Format

Send to

Choose Destination
Urology. 2008 Jun;71(6):1001-6. doi: 10.1016/j.urology.2007.12.070. Epub 2008 Apr 14.

Testosterone surge: rationale for gonadotropin-releasing hormone blockers?

Author information

1
Department of Urology, University Hospital Gasthuisberg, Leuven, Belgium. Hendrik.VanPoppel@uz.kuleuven.ac.be

Abstract

Gonadotropin-releasing hormone (GnRH) agonists currently form the mainstay of management of advanced prostate cancer. They effectively suppress serum testosterone levels, which in turn inhibits tumor growth. However, the initial response to GnRH agonists is a transient increase in the serum testosterone levels. Known as a testosterone surge, this can lead to a worsening of symptoms and can adversely affect survival. Therefore, much interest exists in the development of a new class of drugs-GnRH antagonists-which produce immediate suppression of luteinizing hormone and testosterone without a testosterone surge. The most promising GnRH antagonist to date is degarelix.

PMID:
18407326
DOI:
10.1016/j.urology.2007.12.070
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center